jump to content jump to footer

How to improve reading procedures and reduce errors in clinical trials with imaging endpoints

Dr. Laura Oleaga from Hospital Clinìc de Barcelona explains how she and her team have benefitted from implementing mint Lesion™ in the face of an increasing volume of clinical trials. She highlights how standardized reading procedures and reports limit the possibility of errors in clinical trial work, improve the communication between radiology and oncology, and deliver the necessary documentation for trial audits.

 
Moreover, she decsribes the potential that arises by using mint Lesion™ in their clinical routine – extending clinical trial excellence to the routine care of each oncological patient.

mint Lesion usage during a clinical trial read, featuring the TGRM export tool.
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer

For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…

Read more
Participants at the RECIST and Beyond workshop in Cologne during hands-on training with mint Lesion for structured tumor response assessment.
The two-day “RECIST and Beyond” workshop at radCIO Cologne offered intensive hands-on training on RECIST, iRECIST, mRECIST and LI-RADS, with real-case reporting performed directly in mint Lesion.
Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging

How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?

Read more
Screenshot of the mint Lesion interface showing RANO 2.0 configuration, tumor burden calculations, and structured neuro-oncology assessment tools.
mint Lesion fully supports RANO 2.0 implementation with configurable parameters, automated tumor burden calculations, and structured workflows for neuro-oncology clinical trials.
Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion

Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…

Read more
scroll-top